User login
As we move into a new year, it is worth reflecting on the substantial advances in oncology during 2011. It was a remarkable year, with progress in basic as well as translational research that yielded major new therapies in breast cancer, melanoma, prostate cancer, leukemias, and several other cancers and blood diseases. We saw progress in prevention for breast cancer, in improving cure rates in early-stage diseases, and in prolonging life in several advanced-stage cancers. The publication of data suggesting targeted immunotherapy as a possible cure for patients with advanced refractory chronic lymphocytic leukemia (CLL) should encourage us to prioritize referrals to and participation in clinical trials...
*For a PDF of the full article, click in the link to the left of this introduction.
As we move into a new year, it is worth reflecting on the substantial advances in oncology during 2011. It was a remarkable year, with progress in basic as well as translational research that yielded major new therapies in breast cancer, melanoma, prostate cancer, leukemias, and several other cancers and blood diseases. We saw progress in prevention for breast cancer, in improving cure rates in early-stage diseases, and in prolonging life in several advanced-stage cancers. The publication of data suggesting targeted immunotherapy as a possible cure for patients with advanced refractory chronic lymphocytic leukemia (CLL) should encourage us to prioritize referrals to and participation in clinical trials...
*For a PDF of the full article, click in the link to the left of this introduction.
As we move into a new year, it is worth reflecting on the substantial advances in oncology during 2011. It was a remarkable year, with progress in basic as well as translational research that yielded major new therapies in breast cancer, melanoma, prostate cancer, leukemias, and several other cancers and blood diseases. We saw progress in prevention for breast cancer, in improving cure rates in early-stage diseases, and in prolonging life in several advanced-stage cancers. The publication of data suggesting targeted immunotherapy as a possible cure for patients with advanced refractory chronic lymphocytic leukemia (CLL) should encourage us to prioritize referrals to and participation in clinical trials...
*For a PDF of the full article, click in the link to the left of this introduction.